Reason for request
Reassessment of medicines containing methylphenidate in attention deficit hyperactivity disorder in response to the instruction from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of QUASYM LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years old and over when psychological, educational and social management alone prove insufficient. |
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
nhq1MF5URDzBXTqC
